🏥
🏥 Health
Moderna reports first positive Phase 3 trial for mRNA neoantigen therapy in melanoma
Moderna has announced the first positive Phase 3 clinical trial result for an mRNA-based neoantigen therapy targeting melanoma. The result marks a significant milestone in the development of personalised cancer vaccines using mRNA technology.
Similar stories
Experimental mRNA vaccine shows promise in preventing melanoma recurrence
The Independent World · 1h ago
Moderna's stock doubles after promising mRNA cancer vaccine results
MarketWatch · 2h ago
Moderna-Merck personalised melanoma vaccine extends relapse-free survival in first late-stage trial
CNBC · 4h ago
Comments
No comments yet
Comments
No comments yet — be the first to weigh in 👇
No comments yet. Be the first!